Boston Scientific to Present Key Data at the 2024 American Society of Pain & Neuroscience Conference
Boston Scientific to Present Key Data at the 2024 American Society of Pain & Neuroscience Conference
|
MARLBOROUGH, Mass., July 8, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company's clinical data will be featured at the sixth annual American Society of Pain & Neuroscience (ASPN) conference, which will be held in Miami Beach, Florida, on July 11-14, 2024. A total of 15 abstracts and posters will be presented, including a study of five-year pooled data for the Intracept Procedure System that measures outcomes across three clinical trials. The Intracept procedure system includes the only U.S. Food and Drug Administration cleared devices for the treatment of vertebrogenic low back pain, a distinct type of pain caused by damage to vertebral endplates, which interface between the disc and the vertebral body. The pooled data are based on a five-year follow-up study of 249 patients with vertebrogenic pain and treated with the Intracept procedure system. Patient-reported Oswestry Disability Index (ODI) and numeric pain scores were compared to baseline. Secondary outcomes measured included numeric pain score quartiles, responder rates, patient satisfaction and healthcare utilization. Of the 30 million people in the U.S. with chronic low back pain, one in six are likely to have vertebrogenic pain[1] Patients typically have pain in the middle of their low back, which worsens when they bend over, sit for long periods of time, or when they are active. A physician can confirm a patient's pain is vertebrogenic by observing modic changes, a biomarker seen on standard MRI that indicates inflammation at the vertebral endplate. "Boston Scientific provides innovative solutions that help patients with chronic pain and neurological conditions get back to their daily lives," said Ray Baker, M.D., vice president and chief medical officer, Neuromodulation, Boston Scientific. "The data shared at the 2024 ASPN Annual Meeting demonstrate the clinical effectiveness of our entire interventional pain portfolio, including meaningful clinical evidence on lasting relief from vertebrogenic pain." Additional data to be presented by Boston Scientific include clinical outcomes on FAST Therapy (Fast-Acting Sub-Perception Therapy) with spinal cord stimulation (SCS) as well as one-year results from the SOLIS (SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery) randomized control trial. Featured Presentations Poster presentations:
Oral presentations:
For a complete list of Boston Scientific clinical and scientific data presentations at the 2024 ASPN conference, please visit: . About the Boston Scientific Chronic Pain Portfolio The Boston Scientific portfolio of advanced chronic pain management solutions is designed to deliver lasting relief to improve the quality of life for the millions of people living with pain worldwide. Supported by robust clinical evidence, the comprehensive suite of transformative therapies includes the WaveWriter Alpha Spinal Cord Stimulator System, Intracept Procedure, Radiofrequency Ablation, and the Vertiflex Procedure† to provide safe and effective therapy options that help physicians address the unique needs of their patients. About Boston Scientific Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, product performance and impact, new and anticipated product approvals and launches and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including cost savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release. CONTACTS: Media: Lisa Ferrer Investor Relations: Jon Monson |
Intracept Procedure System = Intracept Intraosseous Nerve Ablation System |
|
2024年7月8日，马尔博勒，波士顿科学公司（纽交所：BSX）宣布公司的临床数据将在第六届美国疼痛和神经科学学会年会（ASPN）上亮相，该年会将于2024年7月11-14日在佛罗里达州迈阿密海滩举行。将展示总共15篇文章和海报，包括一项针对Intracept程序系统的五年汇总数据研究，该系统衡量了三项临床试验中的结果。 Intracept程序系统包括唯一获得美国食品和药物管理局认可的设备，用于治疗脊椎源性下背痛，这是一种由于椎体板损伤引起的不同类型疼痛，介于椎间盘和椎体之间。 汇总数据基于对249名患有脊椎源性疼痛并接受Intracept程序系统治疗的患者进行的为期五年的随访研究。将患者报告的Oswestry残疾指数（ODI）和数字疼痛评分与基线进行比较。其他测量的次要结果包括数字疼痛评分四分位数、反应者比例、患者满意度和卫生保健利用率。 在美国有3000万人患有慢性下背痛，其中六分之一可能患有脊椎源性疼痛[1]，患者通常在低背部中感到疼痛，在弯腰、长时间坐着或运动时疼痛加剧。医生可以通过观察标准磁共振成像上看到的modic变化，即在椎体板处出现的生物标志物来确认患者的疼痛是脊椎源性的。 "波士顿科学提供创新解决方案，帮助患有慢性疼痛和神经疾病的患者回到日常生活中，"波士顿科学神经调制剂副总裁兼首席医疗官Ray Baker 万博士说，"2024年ASPN年会上分享的数据证明了我们整个介入性疼痛组合的临床有效性，包括有关脊椎源性疼痛持久缓解的有意义的临床证据。" 波士顿科学将展示的其他数据还包括使用脊髓刺激（SCS）的FASt治疗（快速亚感知治疗）的临床结果以及SOLIS（作为慢性下背痛和/或腿痛的替代手术的SCS选项）随机对照试验的一年结果。 特色演讲 海报展示:
口头展示:
有关波士顿科学临床和科学数据在2024年ASPN年会上的完整列表，请访问: 有关波士顿科学慢性疼痛组合的介绍 波士顿科学的先进慢性疼痛管理解决方案组合旨在提供持久缓解，改善全球数百万患病人士的生活质量。支持强大的临床证据，全面的变革疗法套件包括WaveWriter Alpha脊髓刺激系统、Intracept程序、射频消融和Vertiflex程序†，提供安全有效的治疗选择，帮助医生应对患者的独特需求。 关于波士顿科学 关于前瞻性声明的警示性声明 本发布将包含适用证券法的前瞻性信息（"前瞻性声明"），涉及Descartes的运输管理解决方案和潜在的由此获得的好处；和其他事项。这样的前瞻性声明涉及已知和未知的风险、不确定性、假设和其他因素，可能导致实际结果、表现或成就不同于预期的结果、表现或成就或发生的发展所表达或暗示的发展。诸如代表性的因素和假设在提交给证券交易委员会、安大略证券委员会和加拿大全国证券委员会的文件中讨论，包括Descartes最近提交的管理层讨论和分析文档中。如果任何此类风险确实发生，他们可能会对我们的业务、财务状况或运营结果造成实质性的负面影响。如果出现这种情况，我们普通股的交易价格可能会下跌，甚至可能趋于实质。读者被警告不要对任何此类前瞻性声明抱有过高的依赖性，这些声明仅在发表之日有效。前瞻性声明是为了提供关于管理层当前的期望和计划，涉及未来的目的。读者被警告，这样的信息可能不适用于其他目的。我们不承担任何更新或修订任何前瞻性声明的任何义务或承诺，以反映任何基于法律要求的期望或任何该声明所基于的事实、情况或环境的任何变化，除非法律规定。 本新闻稿包含根据1933年证券法第27A条和1934年证券交易法第21E条作出的前瞻性声明。可通过像"预计"，"期望"，"计划"，"相信"，"规划"，"估计"，"打算"等词语来确定前瞻性声明。这些前瞻性声明是基于我们在当时可获得的信息使用的信仰、假设和估计，并不旨在成为未来事件或业绩的保证。这些前瞻性声明包括，但不限于，关于我们的商业计划、产品性能和影响、新产品批准和推出以及临床试验的声明。如果我们的基本假设被证明是不正确的，或者如果某些风险或不确定性实现了，实际结果可能会与我们的前瞻性声明所表达或暗示的期望和投影有所不同。这些因素，在某些情况下，已经影响过，未来（连同其他因素）可能影响我们实施业务策略的能力， 并可能导致实际结果与本新闻稿中表述的陈述不符。因此，读者被警告不要对我们的任何前瞻性声明放置过度的依赖。 可能会引起这种差异的因素包括但不限于：未来的经济、政治、竞争、报销和监管条件，新产品推出，人口统计趋势，知识产权，诉讼，金融市场条件，我们的业务战略的执行和影响，包括成本节约和增长举措；我们和我们的竞争对手未来的业务决策。所有这些因素都难以或者不可能准确预测，其中许多因素超出了我们的控制范围。有关这些和其他重要风险和不确定性的完整列表和描述，可能会影响我们未来运营的，请参阅我们最新的10-k年度报告文件的第I部分、第1A条-风险因素，在此之后的季度10-Q报告文件的第II部分，第1A条-风险因素，我们可能会进行更新。 我们否认公开更新或修订任何前瞻性声明，以反映我们的期望或事件、条件或环境的变化，或可能影响实际结果与前瞻性声明中包含的结果不同的可能性，除非法律另有规定。本警告声明适用于本新闻稿中包含的所有前瞻性声明。 联系方式： 媒体： Lisa Ferrer 投资者关系: Jon Monson |
Intracept程序系统 = Intracept骨内神经消融系统 |
[1] Hoy D, March L, Brooks P, et al. The global burden of low back pain; estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases 2014;73:968-974. global point prevalence of LBP was 9.4% (95% CI 9.0 to 9.8), (333M U.S. pop * 9.4% = 31M); Lorio et al. International Journal of Spine Surgery December 2022, 16 (6) 1084-1094; DOI: estimated that 15% of CLBP patients suffer from primary vertebrogenic pain.
[1] Hoy D，March L，Brooks P等。低背痛的全球负担：来自2010年全球疾病负担研究的估计。《风湿病学杂志》2014年；73：968-974。全球患有LBP的点预valence为9.4％（95％CI 9.0至9.8），（33300万美国人口* 9.4％= 3100万）; Lorio等人。2022年12月国际脊柱外科杂志，16（6）1084-1094; DOI：估计15％的CLBP患者患有原发性脊椎源性疼痛。